ࡱ> {y|!` W+bjbj\\ 4f>>~~~~^^^rz-z-z-z-L-rMn.p....)1^2l28MMMMMMM$WOhQ*M-^+30^)1+3+3*M~~..WMs7s7s7+3~.^.Ms7+3Ms7s7H@^I.b. _z-5RIKLmM0MfIR?6$R(IInR^TJd+3+3s7+3+3+3+3+3*M*Mc7+3+3+3M+3+3+3+3rrrrrrrrr~~~~~~ National Pain Management Strategy Coordinating Committee Pharmacy Workgroup Fentanyl Transdermal Patch Dosing and Safety Information Paper Fentanyl transdermal patches have recently been associated with a number of serious adverse events and deaths nationwide. Clinicians should use the fentanyl patch only if they are familiar with the prescribing information. This letter provides clinicians with important information to promote the safe use of the fentanyl transdermal patch. Who Should Receive Fentanyl transdermal patch Fentanyl tranasdermal patch is indicated in patients who have persistent, moderate to severe chronic pain that % requires continuous, around-the-clock opioid administration for an extended period of time, and % cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids. Fentanyl transdermal patch should NOT be used for management of mild, acute, short-lasting, or intermittent pain. It should not be used on an as-needed basis. Fentanyl transdermal patch should ONLY be used in patients who are already receiving opioid therapy, who have demonstrated opioid tolerance, and who require a total daily dose at least equivalent to fentanyl 25 mcg/h. Patients who are considered opioid tolerant are those who have been taking, for a week or longer, at least 60 mg of oral morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily, or an equianalgesic dose of another opioid. Dosing and Administration Converting from Other Opioids to the Fentanyl Transdermal Patch As a general rule, when converting to fentanyl from another opioid, use about 25mcg/h of fentanyl transdermally for every 90 mg of oral morphine equivalent. Appropriate dosage increments should be based on the daily use of supplemental opioids with the equivalency of morphine 45 milligrams/day orally to a 12.5 micrograms/hour increase in the transdermal fentanyl dose. Duragesic-12 delivers 12.5mcg/h of fentanyl.  INITIAL FENTANYL TRANSDERMAL DOSAGE Only for converting another opioid to fentanyl  Adapted from the Duragesic PI, 2007 * The VA/DOD Medications Pocket Guide and equianalgesic opioid conversin ratios may be found at  HYPERLINK "http://www.oqp.med.va.gov/cpg/cot/G/OT_Med.pdf" http://www.oqp.med.va.gov/cpg/cot/G/OT_Med.pdf . Alternatively, the dose of fentanyl can be calculated using the following table. This table should only be used when converting to fentanyl; it should NOT be used when converting from fentanyl to another opioid. The conversion ratios are conservative and may result in overdosage if used to convert fentanyl to other opioids. Prescribe a short-acting opioid analgesic, to be taken by the patient as needed, when fentanyl is first started, since the onset of the analgesic effects of fentanyl may be delayed about 20hours. Titrate patients upwards no more frequently than every 72hours after the initial dose or no more frequently than every 6 days thereafter. Serum fentanyl concentrations increase gradually following initial application of the patch, generally leveling off between 12 and 24 hours and remaining relatively constant, with some fluctuation, for the remainder of the 72-hour application period. Dosage increases made more frequently than the recommended intervals may result in too rapid systemic accumulation of drug and potentially serious toxicity. Do not cut or damage the patch. If the transdermal system is cut or damaged, controlled drug delivery will not be possible, which can lead to the rapid release and absorption of a potentially fatal dose of fentanyl. Converting from Fentanyl to Other Opioids There are no FDA-approved dosing instructions on how to convert patients from fentanyl to other opioids. After discontinuing the fentanyl patch, titrate the new opioid according to the patients level of pain relief and tolerability. Take into consideration the fact that, after removal of the fentanyl patch, serum fentanyl concentrations decline gradually, falling about 50% in approximately 17 (range 13-22) hours. Patient Education Clinicians should educate patients on the proper use, storage, and disposal of fentanyl transdermal patch. Advise patients to wear the patch continuously for 72 hours, and that each patch should be applied to a different skin site after removal of the previous transdermal patch. Patches should be applied to intact, non-irritated, and non-irradiated skin on a flat surface such as the chest, back, flank, or upper arm. Hair at the application site should be clipped (not shaved) prior to patch application. The patch should not be used if the seal is broken, or if it is altered, cut, or damaged in any way prior to application. This could lead to the rapid release of the contents of the patch and absorption of a potentially fatal dose of fentanyl. The transdermal patch should be pressed firmly in place with the palm of the hand for 30 seconds, making sure the contact is complete, especially around the edges. Patients should avoid exposing the application site to direct external heat sources, such as: heating pads, electric blankets, heat lamps, saunas, hot tubs, and heated water beds, etc. If patients develop a high fever while wearing the patch they should contact their physician. Patients should be advised that fentanyl may impair mental and/or physical ability required for the performance of potentially hazardous tasks (e.g., driving, operating machinery). Patients should be made aware of the potential for severe constipation and other opioid side effects. Patients should be informed that, if the patch dislodges and accidentally sticks to skin of another person, they should immediately take the patch off, wash the exposed area with water and seek medical attention for the accidentally exposed individual. Fentanyl TDS should be kept out of the reach of children and pets, preferably in a locked cabinet. Patients should be advised to fold (so that the adhesive side adheres to itself) and immediately flush down the toilet any used fentanyl patches after removal from the skin. Accidental exposure or misuse may lead to death or other serious medical problems. References: Duragesic Patch . Full US Prescribing Information.  HYPERLINK "http://www.duragesic.com/active/janus/en_US/assets/common/company/pi/duragesic.pdf#zoom=100" http://www.duragesic.com/active/janus/en_US/assets/common/company/pi/duragesic.pdf#zoom=100. VA/DoD Clinical Practice Guideline for the Management of Opioid Therapy for Chronic Pain. Medications Pocket Guide.  HYPERLINK "http://www.oqp.med.va.gov/cpg/cot/G/OT_Med.pdf" http://www.oqp.med.va.gov/cpg/cot/G/OT_Med.pdf. Opioid Therapy for Chronic Pain. VA/DoD Clinical Practice Guideline for the Management of Opioid Therapy for Chronic Pain.  HYPERLINK "http://www.oqp.med.va.gov/cpg/cpg.htm" http://www.oqp.med.va.gov/cpg/cpg.htm. Fudin J. Chemical classes of opioids. ( HYPERLINK "http://www.paindr.com/Opioid%20Chemistry%2004-2006.rtf" http://www.paindr.com/Opioid%20Chemistry%2004-2006.rtf) PDR entry for Duragesic Transdermal System (Ortho-McNeil). From MICROMEDEX.  HYPERLINK "http://vaww.visn8.med.va.gov/mdxcgi/htmldisp.exe?CTL=D:\\mdx\\mdxcgi\\MEGAT.SYS&SET=1C6F2BEA9730B810&SYS=3&T=0960&D=1&Q=18" http://vaww.visn8.med.va.gov/mdxcgi/htmldisp.exe?CTL=D:\mdx\mdxcgi\MEGAT.SYS&SET=1C6F2BEA9730B810&SYS=3&T=0960&D=1&Q=18. Adapted from the Duragesic PI, 2007 Calculate the previous 24-hour opioid analgesic requirement. Convert this amount to the equianalgesic oral morphine dose.* The table on the right displays the range of 24-hour oral morphine doses that are recommended for conversion to each fentanyl patch dose. Use this table to find the calculated 24-hour morphine dose and the corresponding fentanyl patch dose. Stop the previous opioid and initiate fentanyl patch treatment using the recommended dose and titrate patients upwards (no more frequently than every 3 days after the initial dose or no more frequently than every 6 days thereafter) until analgesic efficacy is attained. The recommended starting dose when converting from other opioids to fentanyl patch is likely too low for 50% of patients. This starting dose is recommended to minimize the potential for overdosing patients with the first dose. For delivery rates in excess of 100 mcg/h, multiple systems may be used. Oral 24-hour Morphine (mg/day)DURAGESIC Dose (mcg/h)60-13425135-22450225-31475315-404100405-494125495-584150585-674175675-764200765-854225855-944250945-10342751035-1124300 89KLMVh  # , 1 2 n ιwwwogoo_WhZnhq5hZnhX5hZnh`E5hZnh7k5hZnhN5hZnh k5hZnhN5hZnh!p.5hZnhC5hZnh8JK5hZnh35 h35 hq5hZnhq5CJaJh;5CJaJh35CJaJh3CJaJh3h3CJaJh3h CJaJh3hqCJaJ"9LM (  j  N & Fgd3gd=DKh^hgdk & Fgdc 8^8`gdq & Fgd-Ygdq$a$gd &V+  & ( : ^ z    j s   # ƿ޸ƿޱױДzple hZnh3hkhZnh4=5>*hZnh4=\hZnhb5>*hZnh!p.\hZnhb\ hZnhx hZnhBk hZnhN hZnhb hZnhq hZnh=DKhZnh-Y5>* hZnh4= hZnh!p. hZnh-YhZnhq5>*hZnh!p.5hZnhq5#  /3<MNv=Ovogo[T hZnhdhZnh:5CJaJhZnh:5 hZnh: jhZnh |UmHnHuh3 h3hdhZnhw5B*\phhZnhwB*ph h3h3 hZnh| hZnhvQ hZnh H hZnh9=hZnh!p.56hZnh#CD56hZnh#CD5>*hZnh* 5>*hZnh=DK5>* =lgd:gd=DK & FgddVW·ЬmaZSKShZnhw5 hZnhw hZnh|VhZnh~>*CJaJ$hZnh~0J>*B*CJaJph#jhZnh~CJUaJjhZnh~CJUaJhZnh~CJaJhZnhW<CJaJhZnh:CJaJ hZnh: hZnhd hZnh | hZnh~ jhZnh~UmHnHu jhZnh:UmHnHugdYp & Fgd=DK & FgdEc\gd#CD & FgdC & FgdN & Fgdwgd~gdW<gd:gd=DK89^_`[y}+0ʹyrkrkc[hZnhsH5hZnhYp>* hZnh#CD hZnho hZnhn# hZnhEc\hZnh#CD6>*hZnh#CD6 hZnhFhZnhC5>* hZnhChZnhC5hZnhN5>* hZnhY}c hZnhR hZnhN hZnh* hZnhHY hZnhL&hZnhw\  h \!`!!!!!!!!'"("""""""""K#趯~wi~`~wUh8hpB*phh8hp0Jj1h8hpU h8hpjh8hpU h8h h8hP~4 hZnh  hZnhP~4hZnhp5>* hZnhW< hZnh=DK hZnh.4 hZnhpc hZnhx hZnhsH hZnhH ThZnhYp5 hZnhYphZnhn#5hZnh?5 WI h !!!"gdP~4gd  & Fdd[$\$gdW< & Fdd[$\$gdH T & Fdd[$\$gd=DK & Fdd[$\$gd=DK""##$$Z%[%&&&&'O'A(O)|*}*~**gd |gd | & Fdd[$\$gd | & Fdd[$\$gd:gdpgd  7$8$H$gdpgdP~4K#L#f#g#h######S$T$$$$$$$$$$% %!%W%X%[%j%%%%%%1&ҶҶ⃑|tj|_|jh8hUh8hp5\h8hp\ h8hjXh8hpUjh8hpU h8hP~4$jKh8hpB*Uphh8hp0J$jh8hpB*Uphjh8hpB*Uph h8hph8hpB*phh8hB*ph!1&2&3&&&&&&&&''M'O'@(A(N)O)|*}*******************++ ++++'+(+4+5+B+C+M+Q+R+ hwS1h |hwS1h |56H*hKh |5hwS1h |56h |B*^Jphh:h |h~h~h~CJaJhvQ h8hp h8hh8h0Jjh8hUjh8hU4*******$$m q&#$/Ifa$gdwl$$m q&#$/Ifa$gdwl****jKK$$m q&#$/Ifa$gdwlkd$$Ifl  60}N t 6m q0  644 lapyt:****jKK$$m q&#$/Ifa$gdwlkdj $$Ifl  R0}N t 6m q0  644 lapyt:****jKK$$m q&#$/Ifa$gdwlkd $$Ifl  ;0}N t 6m q0  644 lapyt:****jKK$$m q&#$/Ifa$gdwlkdR $$Ifl  R0}N t 6m q0  644 lapyt:****jKK$$m q&#$/Ifa$gdwlkd $$Ifl  R0}N t 6m q0  644 lapyt:***+jKK$$m q&#$/Ifa$gdwlkd: $$Ifl  R0}N t 6m q0  644 lapyt:++ + +jKK$$m q&#$/Ifa$gdwlkd $$Ifl  R0}N t 6m q0  644 lapyt: ++++jKK$$m q&#$/Ifa$gdwlkd" $$Ifl  ;0}N t 6m q0  644 lapyt:++#+'+jKK$$m q&#$/Ifa$gdwlkd $$Ifl  R0}N t 6m q0  644 lapyt:'+(+0+4+jKK$$m q&#$/Ifa$gdwlkd $$Ifl  R0}N t 6m q0  644 lapyt:4+5+>+B+jKK$$m q&#$/Ifa$gdwlkd~ $$Ifl  R0}N t 6m q0  644 lapyt:B+C+M+Q+jKK$$m q&#$/Ifa$gdwlkd $$Ifl  R0}N t 6m q0  644 lapyt:Q+R+S+T+U+V+W+jhhhhcgd kdf$$Ifl  R0}N t 6m q0  644 lapyt:R+T+U+V+W+ h8hphPfh:h |21h:p|/ =!"#$% 1DyK /http://www.oqp.med.va.gov/cpg/cot/G/OT_Med.pdfyK ^http://www.oqp.med.va.gov/cpg/cot/G/OT_Med.pdfDyK \http://www.duragesic.com/active/janus/en_US/assets/common/company/pi/duragesic.pdf#zoom=100yK http://www.duragesic.com/active/janus/en_US/assets/common/company/pi/duragesic.pdf zoom=1001DyK /http://www.oqp.med.va.gov/cpg/cot/G/OT_Med.pdfyK ^http://www.oqp.med.va.gov/cpg/cot/G/OT_Med.pdf DyK &http://www.oqp.med.va.gov/cpg/cpg.htmyK Lhttp://www.oqp.med.va.gov/cpg/cpg.htmIDyK 7http://www.paindr.com/Opioid%20Chemistry%2004-2006.rtfyK fhttp://www.paindr.com/Opioid Chemistry 04-2006.rtfUDyK xhttp://vaww.visn8.med.va.gov/mdxcgi/htmldisp.exe?CTL=D:\mdx\mdxcgi\MEGAT.SYS&SET=1C6F2BEA9730B810&SYS=3&T=0960&D=1&Q=18yK http://vaww.visn8.med.va.gov/mdxcgi/htmldisp.exe?CTL=D:\mdx\mdxcgi\MEGAT.SYS&SET=1C6F2BEA9730B810&SYS=3&T=0960&D=1&Q=18r$$If!vh55#v#v:Vl6 t 6m q65yt:r$$If!vh55#v#v:VlR t 6m q65yt:r$$If!vh55#v#v:Vl; t 6m q65yt:r$$If!vh55#v#v:VlR t 6m q65yt:r$$If!vh55#v#v:VlR t 6m q65yt:r$$If!vh55#v#v:VlR t 6m q65yt:r$$If!vh55#v#v:VlR t 6m q65yt:r$$If!vh55#v#v:Vl; t 6m q65yt:r$$If!vh55#v#v:VlR t 6m q65yt:r$$If!vh55#v#v:VlR t 6m q65yt:r$$If!vh55#v#v:VlR t 6m q65yt:r$$If!vh55#v#v:VlR t 6m q65yt:r$$If!vh55#v#v:VlR t 6m q65yt:@@@ NormalCJ_HaJmH sH tH F@BF Yp Heading 4dd@&[$\$5\DA@D Default Paragraph FontRi@R  Table Normal4 l4a (k(No ListB^@B c Normal (Web)dd[$\$bOb HDefault 7$8$H$-B*CJOJQJ^J_HaJmH phsH tH 4U@4 9= Hyperlink >*phFV@!F FollowedHyperlink >*B* phD2D q Balloon TextCJOJQJaJB'AB * Comment ReferenceCJaJ<R< *  Comment TextCJaJ@jQR@ * Comment Subject5\br@sb |Table Classic 1:V0  j#j#j#jj 9B*`Jph6]5\56\]&W"  &W"f9LMj  N =l  WI hZ[OAO |!}!~!!!!!!!!!!!!!!!!!!!!!!!!!"" " """""#"'"("0"4"5">"B"C"M"Q"R"S"T"U"X"0000000000 000 0 0 000000 0 0000000000000000000000000000000000000 0 0 0 0 00 0  0 8080 0 0 0 0 0 0 07 07 07 07 07 07 0 0 0 0  0  0 000000000000000 0 0 0 0 0000000 000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00000Mj  N =l  WI hZ[OAO |!}!!!!!!!!!!!!!!!!!!!!!!!!!"" " """""#"'"("0"4"5">"B"C"M"Q"R"X"@0@0@0@00 0 00j00/@ 0@ 0 000:0:0:0@ 0 @ 0 @ 0 @ 0 @ 0 @ 0 0+0T@ 0 @ 0 @ 0 0/0n@ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 j0*0,@ 0j0&0"j0&0"j0&0"@ 0 0 :0:0 0 0 0 0 0 0 0T  0T  0T  0T  0T  0T  0@ 0 @ 0 @ 0 0 00'00(0000.00.00.00.0@0@0,09b000 00 00 00@ 00@ 000000,u0+0S0+0T,G0+0S 0+0Q@0d`$j00j00j00j00j00j00j00j00j00j00j00j00j00j0 0j0 0j0 0j0 0j0 0j0 0j00j00j00j00j00j00j00j00j00j00j00j00j00j00j000C080C08j000 ,09b K#1&R+W+"#2"*******+ ++'+4+B+Q+W+ !$%&'()*+,-./01V+V 'gS W2W"XXXXXX8@B(  \   3  "` H   #   V  # "` B S  ?W" t`'t a$It F12 _Hlt148929223 _Hlt148929224 _Hlt148929238 _Hlt148929239 _Hlt148929730 _Hlt148929731 _Hlt148929249 _Hlt148929250 _Hlt148929207 _Hlt148929208 _Hlt148929516 _Hlt14892951733X"@@@@@@@@ @ @ @ @44X"Va#+ )s~<Gt|4 > L T e m f n *JR}"*8@ emjst+3go X"LR[E!\!X"333333333339K=DIt Mg!!!!!!!!!!!!!!!"" """"'"("4"5"B"C"Q"X"X".2iwP(Q2@bbL(Q2@o\@>IAcD$(s G"B"C"M"Q"R"X"@̚L(W"0@0 0@UnknownGz Times New Roman5Symbol3& z ArialQ CGJKNP+ArialMTArial5& zaTahoma?5 : Courier New;Wingdings"qhW&&n@5n@5Y24d 2QHX)? 27Fentanyl Transdermal System (TDS) Informational SummaryWest Palm BeachWest Palm Beach(       Oh+'0( @L l x 8Fentanyl Transdermal System (TDS) Informational SummaryWest Palm Beach Normal.dotWest Palm Beach3Microsoft Office Word@F#@@_n@՜.+,D՜.+,t0 hp  VA Medical Center5\ 8Fentanyl Transdermal System (TDS) Informational Summary Title(X` _PID_HLINKS_NewReviewCycleAX$ >xhttp://vaww.visn8.med.va.gov/mdxcgi/htmldisp.exe?CTL=D:\mdx\mdxcgi\MEGAT.SYS&SET=1C6F2BEA9730B810&SYS=3&T=0960&D=1&Q=18W$. 3http://www.paindr.com/Opioid Chemistry 04-2006.rtfW\P &http://www.oqp.med.va.gov/cpg/cpg.htmW_~/http://www.oqp.med.va.gov/cpg/cot/G/OT_Med.pdfWQoShttp://www.duragesic.com/active/janus/en_US/assets/common/company/pi/duragesic.pdf zoom=100_~/http://www.oqp.med.va.gov/cpg/cot/G/OT_Med.pdfW  !"#$%&'()*+,-./012356789:;=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdeghijklmopqrstuxRoot Entry F_zData 41Table<RWordDocument4fSummaryInformation(fDocumentSummaryInformation8nCompObjq  FMicrosoft Office Word Document MSWordDocWord.Document.89qRoot Entry FP!Y`zData 41Table<RWordDocument4f  !"#$%&'()*+,-./012356789:;=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdeghijklm~՜.+,D՜.+,t0 hp  VA Medical Center5\ 8Fentanyl Transdermal System (TDS) Informational Summary Title(X` _PID_HLINKS_NewReviewCycleAX$ >xhttp://vaww.visn8.med.va.gov/mdxcgi/htmldisp.exe?CTL=D:\mdx\mdxcgi\MEGAT.SYS&SET=1C6F2BEA9730B810&SYS=3&T=0960&D=1&Q=18W$. 3http://www.paindr.com/Opioid Chemistry 04-2006.rtfW\P &http://www.oqp.med.va.gov/cpg/cpg.htmW_~/http://www.oqp.med.va.gov/cpg/cot/G/OT_Med.pdfWQoShttp://www.duragesic.com/active/janus/en_US/assets/common/company/pi/duragesic.pdf zoom=100_~/http://www.oqp.med.va.gov/cpg/cot/G/OT_Med.pdfWSummaryInformation(fDocumentSummaryInformation8}CompObjq